66 /100
HIGH RISK
Score updated May 30, 2026

ENGN — enGene Therapeutics Inc. Dilution Risk Tracker

Track ENGN dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ENGN — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
100
💰 Cash Runway
0
📊 Float Risk
75
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

⛈️
Warning
High probability of dilution event
52%
🔁 Convertible Conversion 60%
• Major convertible overhang: 31% potential dilution
• Convertible risk score very high (85/100)
📉 Score Deterioration 50%
• Score rose 40 points recently (worsening)
• Score in HIGH risk zone (66/100)
💰 Capital Raise 38%
• Active shelf registration ($400M, 323% of market cap)
• Active ATM program with $100M remaining capacity
🔔 Track ENGN — Get forecast alerts →

💹 Market Data

Market Cap$123.93M
Shares Outstanding66.99M
Float22.49M
Cash$275.95M
Debt$33.46M
Short InterestN/A

🏛 Institutional Holdings

10 institutional holders · 42.50M shares
#1 FCPM III Services B.V. 9.63M shares
#2 Perceptive Advisors Llc 5.87M shares
#3 VR Adviser, LLC 4.77M shares
+ 7 more holders Sign up free to view →

📉 Short Interest

Short Interest1.46M
Days to Cover1.0
% of Float6.5%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Oct 31, 2024
xbrl XBRL CONVERTIBLE Oct 31, 2023
8-K 8K EVENT Mar 09, 2026
424B5 ATM Mar 09, 2026
EFFECT EFFECT Mar 02, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track ENGN Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ENGN — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for ENGN
📊 ENGN FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 ENGN Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.